ReviewActa diabetologica2026
Mechanism and treatment progress of endoplasmic reticulum stress pathway in diabetic neuropathy.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological mechanisms and therapeutic advances in diabetic neuropathy.Journal of neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Diabetic neuropathy (DN) is one of the most common chronic complications of diabetes, severely impacting patients' quality of life. Recent studies have demonstrated that endoplasmic reticulum stress (ERS) plays a key role in the development and progression of DN. This article systematically reviews the activation mechanisms of the ERS pathway, its pathological role in DN, and potential therapeutic strategies targeting this pathway. The ER, a crucial site for protein synthesis, folding, and modification in eukaryotic cells, is homeostatically imbalanced, triggering the unfolded protein response (UPR). In the diabetic state, chronic hyperglycemia, oxidative stress, inflammatory factors, and other factors lead to persistent activation of ERS. Through signaling pathways such as PERK, IRE1α, and ATF6, ERS ultimately causes neuronal and Schwann cell apoptosis, mitochondrial dysfunction, and neuroinflammation, promoting the progression of DN. A deeper understanding of the relationship between ERS and DN will not only help elucidate disease mechanisms but also provide a theoretical basis for the development of novel targeted therapies.Diabetic neuropathy (DN) is one of the most common chronic complications of diabetes, severely impacting patients' quality of life. Recent studies have demonstrated that endoplasmic reticulum stress (ERS) plays a key role in the development and progression of DN. This article systematically reviews the activation mechanisms of the ERS pathway, its pathological role in DN, and potential therapeutic strategies targeting this pathway. The ER, a crucial site for protein synthesis, folding, and modification in eukaryotic cells, is homeostatically imbalanced, triggering the unfolded protein response (UPR). In the diabetic state, chronic hyperglycemia, oxidative stress, inflammatory factors, and other factors lead to persistent activation of ERS. Through signaling pathways such as PERK, IRE1α, and ATF6, ERS ultimately causes neuronal and Schwann cell apoptosis, mitochondrial dysfunction, and neuroinflammation, promoting the progression of DN. A deeper understanding of the relationship between ERS and DN will not only help elucidate disease mechanisms but also provide a theoretical basis for the development of novel targeted therapies.
Indexed as
Identifiers
41186739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.